Syndax Pharmaceuticals Inc Contracts & Agreements

Sales Agreement, dated May 26, 2023 (Filed With SEC on May 26, 2023)

Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (Filed With SEC on February 8, 2023)

Form of Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (Filed With SEC on February 8, 2023)

Underwriting Agreement, dated December 6, 2022, by and between the Company and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC (Filed With SEC on December 7, 2022)

Employment Agreement, dated December 1, 2022, by and between the Company and Steve Sabus (Filed With SEC on December 5, 2022)

MUTUAL RELEASE AND SETTLEMENT AGREEMENT (Filed With SEC on August 8, 2022)

Employment Agreement, dated June 8, 2022, by and between the Company and Keith A. Goldan (Filed With SEC on June 13, 2022)

Executive Employment Agreement by and between the Company and Catherine Madigan, M.D., dated as of March 1, 2022 (Filed With SEC on May 9, 2022)

Executive Employment Agreement by and between the Company and Anjali Ganguli, Ph.D., dated as of September 30, 2021 (Filed With SEC on May 9, 2022)

Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of February 2, 2022 (Filed With SEC on March 1, 2022)

Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of February 2, 2022 (Filed With SEC on March 1, 2022)

Non-employee Director Compensation Policy, as amended, dated as of February 2, 2022 (Filed With SEC on March 1, 2022)

First Amendment to the Companys Loan and Security Agreement with the several banks and financial institutions or entities from time-to-time party thereto and Hercules Capital,... (Filed With SEC on March 1, 2022)

Amended and Restated Employment Agreement, dated February 2, 2022, by and between the Company and Briggs W. Morrison, M.D (Filed With SEC on February 3, 2022)

Amended and Restated Employment Agreement, dated February 2, 2022, by and between the Company and Michael A. Metzger (Filed With SEC on February 3, 2022)

Underwriting Agreement, dated December 15, 2021, by and among the Company and Goldman Sachs & Co. LLC (Filed With SEC on December 17, 2021)

Form of Pre-Funded Warrant (2021) (Filed With SEC on December 17, 2021)

Collaboration and License Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021 (Filed With SEC on November 15, 2021)

Stock Purchase Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021 (Filed With SEC on November 15, 2021)

Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan (Filed With SEC on March 12, 2021)

Underwriting Agreement, dated December 8, 2020, by and among the Company, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC (Filed With SEC on December 9, 2020)

Executive Employment Agreement by and between the Company and Daphne Karydas, dated as of July 6, 2020 (Filed With SEC on November 5, 2020)

Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan (Filed With SEC on August 6, 2020)

Amendment No. 12 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated May 12, 2020 (Filed With SEC on August 6, 2020)

Loan and Security Agreement dated February 7, 2020 between Syndax Pharmaceuticals, Inc. and Hercules Capital, Inc (Filed With SEC on May 7, 2020)

Non-employee Director Compensation Policy, as amended, February 12, 2020 (Filed With SEC on May 7, 2020)

Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of April 27, 2020 (Filed With SEC on May 7, 2020)

Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of April 27, 2020 (Filed With SEC on May 7, 2020)

Amended and Restated Executive Employment Agreement by and between the Company and Michael L. Meyers, M.D., Ph.D., dated as of April 27, 2020 (Filed With SEC on May 7, 2020)

Amended and Restated Executive Employment Agreement by and between the Company and Richard P. Shea, dated as of April 27, 2020 (Filed With SEC on May 7, 2020)

Underwriting Agreement, dated April 30, 2020, by and among the Company, Citigroup Global Markets Inc. and Cowen and Company, LLC (Filed With SEC on May 4, 2020)

Description of Capital Stock (Filed With SEC on March 5, 2020)

Form of Pre-Funded Warrant (Filed With SEC on February 4, 2020)

Purchase Agreement between the Company and the Purchasers, dated January 30, 2020 (Filed With SEC on February 4, 2020)

Amendment No. 11 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated July 1, 2019 (Filed With SEC on November 7, 2019)

Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019 (Filed With SEC on November 7, 2019)

Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019 (Filed With SEC on May 8, 2019)

Form of Series Warrant (Filed With SEC on March 29, 2019)

Form of Pre-Funded Warrant (Filed With SEC on March 29, 2019)

Purchase Agreement between the Company and the Purchasers, dated March 26, 2019 (Filed With SEC on March 29, 2019)

Purchase Agreement between the Company and the Purchaser, dated March 28, 2019 (Filed With SEC on March 29, 2019)

Amendment No. 10 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated October 15, 2018 (Filed With SEC on March 7, 2019)

Amendment #4 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated May 29, 2018 (Filed With SEC on August 8, 2018)

Form of Warrant Agreement (Filed With SEC on June 20, 2018)

Exchange Agreement between Syndax Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P., dated... (Filed With SEC on June 20, 2018)

Amendment #3 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated March 27, 2018 (Filed With SEC on May 9, 2018)

Amendment No. 9 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated November 22, 2017 (Filed With SEC on March 8, 2018)

License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of October 13, 2017 (Filed With SEC on March 8, 2018)

Purchase Agreement, dated October 17, 2017 (Filed With SEC on October 20, 2017)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 10, 2017)

AMENDMENT NO. 1 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR NON-SMALL CELL LUNG CANCER STUDY WITH EXPANSION COHORTS INNON-SMALL CELL LUNG CANCER, MELANOMA, AND... (Filed With SEC on August 10, 2017)

3,750,000 Shares SYNDAX PHARMACEUTICALS, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT (Filed With SEC on May 25, 2017)

AMENDMENT NO. 7 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on May 9, 2017)

AMENDMENT #2 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on May 9, 2017)

AMENDMENT NO. 8 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on May 9, 2017)

SIDE AGREEMENT to the License Agreement dated 1st July 2016 between UCB Biopharma Sprl and Syndax Pharmaceuticals, Inc. (License Agreement) (Filed With SEC on May 9, 2017)

LICENSE AGREEMENT (Filed With SEC on October 7, 2016)

AMENDMENT NO. 3 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)

AMENDMENT NO. 4 TO CLINICAL TRIAL AGREEMENT E2112 BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)

AMENDMENT NO. 5 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)

AMENDMENT NO. 6 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)

AMENDMENT NO. 2 TO CLINICAL TRIAL AGREEMENT E2112 BETWEEN ECOG-ACRIN CANCER RESEARCHGROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on February 22, 2016)

FIRST AMENDMENT (Filed With SEC on February 22, 2016)

AMENDMENT # 1 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on February 22, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 22, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 10, 2016)

CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (Filed With SEC on January 11, 2016)

Shares Syndax Pharmaceuticals, Inc. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. WARRANT CERTIFICATE (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

WARRANT AGREEMENT between SYNDAXPHARMACEUTICALS, INC. and BAYER SCHERING PHARMA AG Dated as of March 26, 2007 Table of Contents (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2007 STOCK PLAN (Filed With SEC on January 4, 2016)

AMENDMENT TO SYNDAXPHARMACEUTICALS, INC. 2007 STOCK PLAN (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2007 STOCK PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2015 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2015 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2015 OMNIBUS INCENTIVE PLAN NON-QUALIFIED OPTION AGREEMENT (Filed With SEC on January 4, 2016)

SYNDAX PHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on January 4, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on January 4, 2016)

Exhibit A (Filed With SEC on January 4, 2016)

GENERAL RELEASE AND POST-SEPARATION CONSULTING AGREEMENT (Filed With SEC on January 4, 2016)

INDEMNIFICATION AGREEMENT (Filed With SEC on January 4, 2016)

LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)

FIRST AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)

SECOND AMENDMENT TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)

THIRD AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)

CLINICAL TRIALAGREEMENT (Filed With SEC on January 4, 2016)

AMENDMENT NO. 1TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on January 4, 2016)

SOLAR CAPITAL LOAN ANDSECURITY AGREEMENT (Filed With SEC on January 4, 2016)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on January 4, 2016)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on January 4, 2016)

CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR NON-SMALL CELL LUNG CANCER STUDY WITH EXPANSION COHORTS IN NON-SMALL CELL LUNG CANCER AND MELANOMA) (Filed With SEC on January 4, 2016)

LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Dated December 19, 2014 by and between SYNDAXPHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO., LTD. (Filed With SEC on January 4, 2016)

[signature pages follow] Syndax Pharmaceuticals,Inc., 400 Totten Pond Road, Suite 110, Waltham, MA 02451 Telephone: 781 ###-###-#### Fax: 781 ###-###-#### (Filed With SEC on January 4, 2016)

COMBINATION STUDY COLLABORATION AGREEMENT BETWEEN GENENTECH, INC. AND SYNDAX PHARMACEUTICALS, INC. TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

CONVERTIBLE UNSECURED PROMISSORY NOTE (Filed With SEC on November 21, 2014)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 21, 2014)

SYNDAX PHARMACEUTICALS, INC. CONVERTIBLE NOTE PURCHASE AGREEMENT (Filed With SEC on November 21, 2014)

SOLAR CAPITAL LOAN ANDSECURITY AGREEMENT (Filed With SEC on June 18, 2014)

SyndaxPharmaceuticals, Inc. Common Stock ($0.0001 Par Value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on May 16, 2014)

LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on May 16, 2014)

TABLE OF CONTENTS Section 1 Definitions Section 2 Grant and Reservation of Rights Section 3 Economic Consideration Section 4 Sublicensing Section 5 U.S. Government Rights Section... (Filed With SEC on May 16, 2014)

SYNDAX PHARMACEUTICALS, INC. WARRANT CERTIFICATE (Filed With SEC on March 27, 2014)

SYNDAXPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on March 27, 2014)

WARRANT AGREEMENT between SYNDAXPHARMACEUTICALS, INC. and BAYER SCHERING PHARMA AG Dated as of March 26, 2007 Table of Contents (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2007 STOCK PLAN (Filed With SEC on March 27, 2014)

AMENDMENT TO SYNDAXPHARMACEUTICALS, INC. 2007 STOCK PLAN (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2007 STOCK PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2013 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2013 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2013 OMNIBUS INCENTIVE PLAN NON-QUALIFIED OPTION AGREEMENT (Filed With SEC on March 27, 2014)

SYNDAX PHARMACEUTICALS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on March 27, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 27, 2014)

INDEMNIFICATION AGREEMENT (Filed With SEC on March 27, 2014)

LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)

FIRST AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)

SECOND AMENDMENT TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)

THIRD AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)

TABLE OF CONTENTS Section 1 Definitions Section 2 Grant and Reservation of Rights Section 3 Economic Consideration Section 4 Sublicensing Section 5 U.S. Government Rights Section... (Filed With SEC on March 27, 2014)

LOAN AND SECURITY AGREEMENT (Filed With SEC on March 27, 2014)

CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)

CONSENTAND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)

CLINICAL TRIALAGREEMENT (Filed With SEC on March 27, 2014)